高视医疗(02407)发布公告，公司附属公司高视创新科技有限公司(高视创新)的"频域生物测量仪"近日已 获得由江苏省药品监督管理局批准的医疗器械注册证。 2023年国家卫健委发布的《中国眼健康白皮书》指出，中国青少年总体近视率约为53.6%。随着近视群 体的不断扩大，近视防控需求的市场也迅速增加。沙利文发布的《中国眼镜镜片行业研究白皮书》指 出，近年来我国近视防控市场规模不断增长，2022年后开始加速，2023年市场规模已经达到人民币 146.8亿元，同比增长43.2%。生物测量仪是近视防控的关键设备，能够对眼轴长度、角膜曲率、晶体厚 度等进行微米级的精确测量，从而能够在监测青少年近视进展、评估近视防控手段的疗效等方面起到重 要作用，同时也是近视屈光手术术前精准评估必不可少的设备之一。 高视创新本次获批的频域生物测量仪(注册证编号：苏械注准20252161508)，基于新一代频域测量原理 开发，相对于大部分传统基于时域原理的同类生物测量仪产品，频域测量原理具有更高的解析度、更快 的成像速度以及更好的信噪比。设备还采用了创新的双光路设计(专利号：CN118526152A)，在进行眼 部参数测量时能够对患者角膜、 ...

Core Insights - GaoShi Medical's subsidiary GaoShi Innovation Technology has received approval for its "Frequency Domain Biometer" from the Jiangsu Provincial Drug Administration, marking a significant advancement in the company's product offerings [1][2] - The demand for myopia prevention and control is rapidly increasing in China, with the overall myopia rate among youth at approximately 53.6% according to the National Health Commission's "China Eye Health White Paper" [1] - The myopia prevention market in China has seen substantial growth, reaching a market size of RMB 14.68 billion in 2023, representing a year-on-year increase of 43.2% [1] Company Insights - The Frequency Domain Biometer, with registration number SuXieZhuZhun 20252161508, is developed based on a new generation of frequency domain measurement principles, offering higher resolution, faster imaging speed, and better signal-to-noise ratio compared to traditional time-domain products [2] - The device features an innovative dual optical path design, allowing for real-time cross-sectional imaging of the cornea, retina, and choroid during eye parameter measurements, which aids in monitoring myopia progression and screening for complications [2] - GaoShi Innovation has independently developed the device over two years, achieving 100% localization of key optical, mechanical, and electrical components [2]

格隆汇8月4日丨高视医疗(02407.HK)宣布，公司附属公司高视创新科技有限公司("高视创新")的「频域 生物测量仪」近日已获得由江苏省药品监督管理局批准的医疗器械注册证。 高视创新本次获批的频域生物测量仪(注册证编号：苏械注准20252161508)，基於新一代频域测量原理 开发，相对於大部分传统基於时域原理的同类生物测量仪产品，频域测量原理具有更高的解析度、更快 的成像速度以及更好的信噪比。设备还采用了创新的双光路设计(专利号：CN118526152A)，在进行眼 部参数测量时能够对患者角膜、视网膜、脉络膜进行即时断层成像，从而在近视随访的同时辅助医生进 行近视并发症的筛查。该设备由高视创新独立自主研发，历时两年，目前已经实现了光、机、电相关关 键零件的100%国产化。 2023年国家卫健委发布的《中国眼健康白皮书》指出，中国青少年总体近视率约为53.6%。随着近视群 体的不断扩大，近视防控需求的市场也迅速增加。沙利文发布的《中国眼镜镜片行业研究白皮书》指 出，近年来我国近视防控市场规模不断增长，2022年後开始加速，2023年市场规模已经达到人民币 146.8亿元，同比增长43.2%。生物测量仪是近视 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 2023年國家衛健委發佈的《中國眼健康白皮書》指出，中國青少年總體近視率約 為53.6%。隨著近視群體的不斷擴大，近視防控需求的市場也迅速增加。沙利 文發佈的《中國眼鏡鏡片行業研究白皮書》指出，近年來我國近視防控市場規 模不斷增長，2022年後開始加速，2023年市場規模已經達到人民幣146.8億元， 同比增長43.2%。生物測量儀是近視防控的關鍵設備，能夠對眼軸長度、角膜 曲率、晶體厚度等進行微米級的精確測量，從而能夠在監測青少年近視進展、 評估近視防控手段的療效等方面起到重要作用，同時也是近視屈光手術術前 精準評估必不可少的設備之一。 – 1 – 高視創新本次獲批的頻域生物測量儀（註冊證編號：蘇械注准20252161508）， 基 ...

Core Viewpoint - The article highlights the growing concern over the marketing and regulation of eye care devices, particularly reading tables and distant screens, which claim to prevent myopia but lack clear medical certification and standards [1][2][10]. Group 1: Industry Standards and Regulations - Current eye care devices like reading tables and distant screens are primarily classified under 3C certification, which is for consumer electronics, rather than as medical devices [8][9]. - There is a significant absence of national standards for these products, with only industry association standards available, leading to confusion and potential consumer deception [10][14]. - Experts call for the establishment of clear regulations and standards to prevent the commercialization of myopia prevention claims and ensure consumer safety [1][16]. Group 2: Consumer Concerns and Misleading Marketing - Many parents are misled by marketing claims that these devices can prevent myopia, often influenced by endorsements from well-known doctors [2][15]. - Some products falsely present themselves as medical devices by showcasing medical registration certificates, which can confuse consumers regarding their actual classification [8][9]. - The marketing strategies employed by companies often exaggerate the effectiveness of these devices, leading to potential violations of advertising laws [15][17]. Group 3: Market Dynamics and Future Directions - The eye care device market is rapidly evolving, with numerous brands entering the space and introducing new products, but the lack of unified standards hampers quality assurance [11][14]. - The increasing prevalence of myopia among children, with rates reported at 52.7% overall, underscores the urgent need for effective and regulated solutions [16]. - Industry experts advocate for a clear classification of these devices based on their intended use and risk, suggesting that those with medical claims should be regulated as medical devices [17][18].

Core Viewpoint - The AI Fund ICBC Healthcare Stock (000831) reported a profit of 209 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1826 yuan, and a net asset value growth rate of 5.88% during the period [2]. Fund Performance - As of July 18, the fund's net asset value growth rates were 17.16% over three months, 28.87% over six months, 26.93% over one year, and -9.65% over three years, ranking 45/54, 38/54, 41/53, and 26/46 among comparable funds respectively [3]. - The fund's Sharpe ratio over the past three years was -0.0674, ranking 25/46 among comparable funds [9]. - The maximum drawdown over the past three years was 36.8%, with the largest single-quarter drawdown occurring in Q3 2022 at 24.01% [11]. Fund Composition and Strategy - As of June 30, the fund maintained an average stock position of 88.71% over the past three years, slightly above the comparable average of 88.19% [14]. - The top ten holdings of the fund as of Q2 2025 included companies such as Heng Rui Medicine, Kelun Pharmaceutical, and BeiGene, among others [19]. Market Outlook - The fund manager expressed optimism regarding long-term trends in refractive surgery technology, increasing penetration rates for myopia prevention, and growth in dental implants and medical aesthetics [2]. - The medical device sector is expected to face challenges in 2024, but a turning point may occur in the second half of 2025 as companies begin to alleviate inventory pressures [2].

Group 1 - The Ministry of Education held a meeting to promote the development of basic education in border areas, focusing on improving public service quality and establishing "border schools" [1] - The National Primary and Secondary School Smart Education Platform launched anti-drug promotional videos to enhance awareness among youth regarding substance abuse [2] - The Ministry of Education released a Q&A on myopia prevention during summer vacation, emphasizing the importance of outdoor activities for at least 2 hours daily to effectively prevent myopia [3] Group 2 - Beijing's transportation authority has cleared over 800 illegally deployed "parent-child bicycles" as part of a special rectification action, identifying three trading platforms and 19 illegal operators [4] - Xueda Education announced that its shareholder, Zhejiang Taizhou Yelinwan Investment Co., Ltd., pledged 5.6 million shares, accounting for 44.98% of its holdings and 4.60% of the company's total share capital [5] - As of the announcement date, the shareholder has cumulatively pledged 12.42 million shares, representing 99.77% of its total holdings and 10.19% of the company's total share capital [5]

Core Viewpoint - The high-priced eye care device "Far Vision Screen" priced at 12,000 yuan is facing strong criticism from parents due to its ineffectiveness and adverse effects on children's eyesight [1][6][11]. Group 1: Product Effectiveness - Multiple parents reported that after using the Far Vision Screen, their children's eye axis length increased instead of stabilizing, leading to concerns about the device's effectiveness [1][6]. - One parent observed that her child's eye axis grew by 0.08mm in the first three months of using the device, while it had previously only increased by 0.01mm without it [5][6]. - The device's claims of preventing myopia are being challenged by medical professionals who emphasize that proper eye care and outdoor activities are more effective [1][12]. Group 2: Customer Experience - Parents expressed frustration over the customer service's contradictory advice, which suggested that more usage is better, despite their children's discomfort and worsening eyesight [9][10]. - Reports from parents on social media platforms indicate widespread dissatisfaction, with many stating that the device did not deliver the promised results and even caused their children's vision to deteriorate [6][10]. - One parent described feeling misled after spending a significant amount on the device, only to find it ineffective and harmful [9][11]. Group 3: Medical Insights - Medical professionals indicate that the primary cause of myopia is prolonged focus on fixed distances, which can lead to eye strain and fatigue [11][12]. - The Far Vision Screen's design aims to simulate outdoor viewing conditions, but experts argue that its actual impact on preventing myopia is minimal [11][12]. - Recommendations for effective eye care include maintaining proper eye hygiene, ensuring adequate outdoor activity, and providing balanced nutrition and sleep [12].

Core Viewpoint - The article discusses the issues surrounding the Anmu Jia reading and writing platform, which has gained popularity on social media but has raised concerns regarding its effectiveness and user experience, particularly in relation to eye health and vision improvement [1][15]. Group 1: Product Performance and User Experience - Consumers have reported that the Anmu Jia reading and writing platform exhibits a noticeable visual distortion, described as a "depression" in the center of the screen, which affects the reading experience [2][4][6]. - Some users, including parents, have experienced discomfort such as dizziness after using the device, leading to questions about its suitability for all users [9][11][13]. - The company acknowledges that individual differences may lead to varied reactions and suggests that consumers should try the product before purchasing [1][6]. Group 2: Market Response and Consumer Behavior - Despite the reported issues, the Anmu Jia reading and writing platform has sold over 10,000 units, with a return rate of approximately 10%, indicating a significant market presence [15]. - Parents are motivated by the desire to improve their children's vision and are willing to invest in such devices, reflecting a broader trend of anxiety regarding childhood myopia [14][16]. - The marketing strategies employed by companies often target parental concerns about vision health, which may lead to impulsive purchasing decisions without thorough evaluation of product quality [16][17]. Group 3: Expert Opinions and Recommendations - Eye care professionals suggest that while the reading and writing platform may help improve posture and reduce the tendency to look down, its overall effectiveness in myopia prevention remains uncertain and requires further clinical research [16]. - Experts recommend that consumers carefully assess the qualifications and certifications of eye care devices before purchase, emphasizing the importance of trying products in-store when possible [16].

Core Viewpoint - The article highlights the innovative approach of Shanghai Ruisi Health Technology Co., Ltd. in integrating eye care products into the daily lives of children and adolescents, focusing on the prevention and control of myopia through advanced technology and clinical validation [3][12]. Company Overview - Ruisi Technology was established in 2017 and has developed AI-based optical brain nerve regulation technology, combining artificial intelligence, optical engineering, and clinical optometry to innovate in myopia management [3][5]. - The company has created a range of products, including the D1 vision training device and the Far Vision Light Screen PLUS 2.0, which utilize proprietary digital technology to provide personalized visual adjustments [5][8]. Clinical Validation - Multi-center clinical studies conducted by reputable institutions have shown that Ruisi's products significantly slow down the progression of myopia, with results indicating a 50% reduction in eye axis shortening and an 80% decrease in myopia degree in certain trials [8][9]. - The company has established a complete trust system from clinical data to academic certification, ensuring the long-term safety and effectiveness of its products [9]. Market Strategy and Future Plans - The recent funding will be directed towards two main areas: advancing medical qualifications through the registration of medical devices and enhancing technology and market reach [11]. - Ruisi aims to create a closed-loop service system that integrates detection, training, and feedback, targeting users aged 3 to 18 and expanding its presence across over 400 cities in China [11][12]. Industry Impact - Ruisi Technology plays a leading role in promoting industry standardization, having co-hosted the release of the first domestic standards for far vision technology, which aims to provide scientific backing for the industry [9][12]. - The company is positioned to address the high prevalence of myopia among children and adolescents in China, with significant social value and market potential [12].